Call to Schedule Free Consultation at Over 45 Centers Worldwide!
Call to Schedule Free Consultation at Over 45 Centers Worldwide!
Find COPD Relief with Stem Cell Therapy
For Your Free Consultation, Call Us Today at: (844) GET-STEM
Free Download: Stem Cell Therapy for COPD
Disclaimer:
The information provided by R3 Stem Cell is for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Individual results may vary and are not guaranteed. The FDA considers stem cell therapy experimental at this point.
Any claims made on this website refer to procedures performed OUTSIDE of the USA. R3 Stem Cell has clinics in Mexico, Philippines, South Africa, Turkey, India, Pakistan.
Please fill out the form below to receive the guide
Every day, R3 Stem Cell receives inquiries worldwide from individuals asking if stem cell therapy can help with COPD. Spoiler alert: it can help significantly! In this guide, we’ll go over the basics of how stem cells work to improve lung function, the latest research findings, and what to expect from a regenerative treatment.
Chronic obstructive pulmonary disease (COPD) is a worldwide epidemic, affecting over 200 million people and causing more than three million deaths annually. According to the World Health Organization (WHO), COPD is now the third leading cause of death globally, following heart disease and cancer. Over the next 20 years, the WHO predicts that COPD-related mortality will more than double.
COPD is defined by chronic inflammation of the airways and progressive destruction of lung tissue, often triggered by cigarette smoking.
Unfortunately, aside from supplemental oxygen and smoking cessation for continuing smokers, there are no proven treatments to extend survival in COPD patients or fully restore lost lung function.
Take a Breath of Relief – Call (844) GET-STEM Today
moking is by FAR the most common reason people develop COPD. Another factor, a hereditary condition called alpha-1 antitrypsin (AAT) deficiency, may also cause lung damage and lead to COPD.
COPD is usually caused by smoking, which accounts for as many as 8 out of 10 COPD-related deaths. However, 1 out of 4 Americans with COPD has never smoked cigarettes.
Mounting evidence shows that COPD progression can slow if at-risk patients quit smoking. Lifelong smokers have a 50% probability of developing COPD during their lifetime. More importantly, smoking cessation can cut the risk of developing COPD by about half.
The exact biological mechanisms causing emphysema and airway remodeling in COPD are not fully understood. One leading theory, the “inflammatory hypothesis,” suggests that in genetically susceptible individuals, lung inflammation—triggered by factors like air pollution and cigarette smoke—changes from a “normal” response to a chronic, abnormal state.
Chronic inflammation leads to structural and functional changes, including:
These changes decrease the airways’ ability to stay open during exhalation, leading to difficulty breathing.
Interestingly, even after the environmental trigger (like cigarette smoke) is removed, the abnormal inflammatory response in the airways may persist. Former smokers often continue to display airway inflammation despite smoking cessation.
Discover If Stem Cell Therapy is Right for You – (844) GET-STEM
The management of COPD includes multiple approaches, such as primary and secondary prevention, early detection, staging the severity of the disease, assessing reversibility with bronchodilators and inhaled corticosteroids, chronic pharmacotherapy, pulmonary rehabilitation, and treating associated comorbidities.
In cases where respiratory failure is detected, long-term oxygen therapy is commonly prescribed. For some patients, especially those with emphysema, lung surgery options, such as lung volume reduction surgery, may be considered.
Medications used in COPD therapy may include:
These medications can reduce airflow obstruction, lower the frequency of exacerbations, and improve the quality of life for patients. However, none of these treatments can halt the progression of COPD or significantly reduce the mortality rate.
Start Your COPD Recovery Journey – Dial (844) GET-STEM
If a new technology such as mesenchymal stem cell and exosome therapy could either reverse COPD or stop the progression, it would and should become first line therapy. A regenerative therapy that can initiate restoration of lung function and is a safe option should receive consideration.
Currently, most COPD treatments focus on symptom relief but do not prevent disease progression or regenerate the lung structure and function. However, recent research suggests that stem cells can achieve these therapeutic goals.
One of the largest clinical trials, conducted by Weiss et al., included 62 patients with COPD. These patients received four monthly infusions of either umbilical cord-derived mesenchymal stem cells (MSCs) or a placebo and were followed over two years. The study showed that MSC infusions were well-tolerated, with no serious or clinically significant adverse effects. Additionally, patients receiving MSCs experienced a statistically significant decrease in C-reactive protein (CRP) one month after the first infusion and throughout the study, although lung function tests and quality-of-life scores did not show significant changes.
In a 2009 study by Stessuk et al., intravenous stem cells were administered to COPD patients, showing improvements in lung function, slower tissue degeneration, enhanced clinical condition, and better quality of life, with no reported side effects. This treatment also led to increased Cluster of Differentiation 31 (CD31) markers, indicating a protective effect and healing response for tissue damage.
A 2020 study in Vietnam by Le Thi Bich et al. administered umbilical cord-derived MSCs (UC-MSCs) to 20 COPD patients, with each patient receiving one infusion of 1.5 million stem cells per kilogram. The study found improvements after six months, including reduced CRP levels, lower exacerbation rates, and a slight increase in the 6-minute walk test (6MWT) score, particularly for stage D patients. The researchers concluded that systemic UC-MSC administration appears safe for moderate-to-severe COPD patients and can significantly improve quality of life.
A 2021 case report, also from Vietnam, investigated autologous adipose-derived stem cells in a 57-year-old male with long-standing COPD who had quit smoking after 15 pack-years. He received one IV infusion initially, followed by another at six months. His dyspnea and quality of life showed improvement at six and twelve months, and the 6MWT score increased over time. The CRP level remained mostly unchanged, while pulmonary function showed a slight improvement. The patient experienced no acute exacerbations throughout the one-year follow-up. At twelve months, a chest CT revealed a slight increase in inhaled total lung volume, with no significant change in the emphysema index.
If you are ready to get started with seeing if you are a good candidate for stem cell therapy for COPD, call us now at (844) GET-STEM.
R3 previously offered autologous therapies, using a patient’s own bone marrow or adipose stem cells. However, because these stem cells age along with the individual, they tend to be less active, especially in older COPD patients.
Age-related factors, including oxidative stress, shortened telomere length, DNA damage, disease, and long-term medication use, impair the therapeutic effectiveness of autologous stem cells for treating COPD.
In contrast, neonatal tissue-derived stem cells from umbilical cord sources present a more youthful genotype and phenotype, providing enhanced anti-inflammatory and immunomodulatory efficacy.
Due to the superior results observed with umbilical cord stem cells, R3 Stem Cell now exclusively uses donor stem cells, offering a more effective regenerative solution for COPD patients.
Get Personalized COPD Treatment Advice – Dial (844) GET-STEM
Stem cells and exosomes support the body through various mechanisms. Importantly, they do not integrate into a patient’s DNA or engraft with existing cells. Instead, they work through these targeted actions:
Additionally, stem cells release a wide variety of molecules into the extracellular environment. These include extracellular vesicles, lipids, free nucleic acids, and soluble proteins, which play vital roles in tissue repair. Along with mesenchymal stem cells (MSCs) for lung disease treatment, R3 Stem Cell also provides exosomes that aid in extensive cell-to-cell communication crucial for lung tissue repair and regeneration.
To learn more or to speak with our stem cell specialists for COPD call us today at (844) GET-STEM.
R3 Stem Cell’s regenerative biologics are derived from umbilical cord tissue donated after a planned C-section. Neither the baby nor the mother is harmed during this procedure. While umbilical cord tissue is typically discarded, it is repurposed here if the mother passes rigorous screening tests mandated by the FDA and other global regulatory agencies.
Once collected, the tissue undergoes careful processing to produce high-quality stem cells and exosomes under strict compliance with the FDA and cGMP standards, ensuring top safety and efficacy for lung therapy.
At R3 Stem Cell’s Centers of Excellence worldwide, umbilical cord stem cell-derived exosomes are used alongside umbilical cord stem cells to enhance therapeutic outcomes. Exosomes are lipid-bound vesicles (acellular) produced by cells and contain an array of growth factors, cytokines, mRNA, and other proteins.
These exosomes are highly effective in cell-to-cell communication and are particularly useful for reducing inflammation. Once absorbed by recipient cells, they act as shuttles, transferring nucleic acids and proteins to other cells, allowing for molecule transport across both close and distant cells. Generally, these released proteins are critical regulators of intracellular communication.
Exosomes can mediate many of the therapeutic activities associated with stem cells. Notably, they have been observed to act faster than stem cells alone, so R3 Stem Cell often combines them with stem cell therapy for a “1-2 punch” effect, optimizing patient outcomes.
Get Started on Your Path to COPD Relief – (844) GET-STEM.
With over a decade of experience and 23,000 stem cell procedures performed globally, R3 Stem Cell has demonstrated that its regenerative treatments are safe. The quality control used in stem cell production is exceptional, and any side effects are generally mild and temporary.
Some mild, short-lived side effects include itching, dizziness, lightheadedness, low-grade fever, chills, headache, and nausea. If an allergic reaction to a multivitamin or preservative occurs, R3 Centers are equipped to manage it quickly with the necessary medications.
One common question is, “Will the stem cells be rejected?” The answer is no.
Mesenchymal stem cells (MSCs) do not express major histocompatibility complex (MHC) antigens of the class II subtype and contain low levels of MHC molecules of the class I subtype. MSCs also lack co-stimulatory molecules like CD40, CD80, and CD86 needed for immune detection, making them low-immunogenic and reducing the risk of immune rejection. Scientists refer to this as being “immunologically privileged.”
Another common concern is, “Can stem cell therapy cause tumors?” Current research confirms that the answer is no. The mesenchymal stem cells and exosomes used in R3’s treatments have not demonstrated any tumor-forming potential. In fact, studies show they possess anti-tumor properties.
Let stem cell treatment help your COPD and to breathe freely again. Call our experienced specialists now at (844) GET-STEM.
For over a decade, R3 Stem Cell have successfully treated lung disease patients using IV and nebulizer stem cell and exosome therapy. Stem cells and exosomes naturally target areas of inflammation, which are prevalent in lung diseases. Therefore, they primarily go to the lungs but also target other areas in need of healing.
For example, if a person has both COPD and diabetes, the stem cells and exosomes will also travel to the pancreas to aid in its function. There is no need to inject directly into the trachea, which would increase risk without added benefit.
R3’s providers determine the appropriate stem cell dosage based on a patient’s weight and COPD severity, generally ranging from 1 to 3 million stem cells/kg. To ensure optimal safety, treatments may be split into two or three sessions, depending on the total stem cell count required.
R3 Stem Cell’s lung disease protocols are founded on the latest research and best practices developed over the past decade, ensuring each patient receives safe, effective care. Safety is prioritized, with biologic products rigorously tested before use, and treatments are administered with the same care as for a family member.
Similar to clinical studies, R3 Stem Cell’s COPD outcomes have been exceptional, with a patient satisfaction rate of 85% year-over-year. Most patients report better breathing, a reduced need for supplemental oxygen, and improved mobility. While results vary between individuals, R3 Stem Cell consistently observes improvements in pulmonary function and other lab results.
Improvements may take several months to fully manifest, though some patients feel better within the first few weeks. It’s important to note that stem cell therapy is not a cure for COPD; repeat treatments every 6 to 12 months are recommended to maintain benefits.
Since stem cell therapy is not a permanent cure, affordability is essential. Repeat treatments can help maintain improvements in lung function. Many patients return to R3 Stem Cell every six to eighteen months for follow-up treatments.
While clinics in Colombia, China, and Panama may charge over $20,000 for lung disease treatment, R3 Stem Cell offers treatments at less than half that cost for 100 million high-quality stem cells!
Begin Your Journey to COPD Relief – Call (844) GET-STEM.
For the past decade, R3 Stem Cell Centers across six countries have performed over 23,000 regenerative procedures, including hundreds for COPD and pulmonary fibrosis. The patient satisfaction rate across all conditions treated is 85%.
R3 Stem Cell prioritizes safety, effectiveness, and affordability. Internationally, Intellicell technology is used, culturing the most active mesenchymal stem cells to create what R3 calls the “smartest” stem cells available.
R3 Stem Cell offers free consultations to help individuals determine if regenerative therapy is right for their COPD. Call +1 (844) GET-STEM or +1 (480) 808-7057 to schedule your consultation today!
Disclaimer: R3 Stem Cell is offering stem cell therapy for COPD and other lung diseases outside of the USA. This guide’s education does not constitute medical advice. The USA FDA is considering experimental stem cell therapy.
References
Brand Ambassador Gallery
The USA stem cell leader offers procedures in
7 Countries including:
SUCCESS STORIES
R3 STEM CELL MASTER CLASS
Learn everything you need to know about the ever expanding field of regenerative medicine in this 8 part series that includes over four hours of entertaining content!
R3 STEM CELL INTERNATIONAL
R3 Stem Cell International includes 45 clinics in 7 countries. These Centers of Excellence treat all types of conditions with safe, effective protocols by expert stem cell physicians.
FREE STEM CELL CONSULTATION
R3 Stem Cell offers a no cost consultation to see if you or a loved one is a candidate for regenerative cell therapies including cytokines, growth factors, exosomes, and stem cells.
PROVIDER PARTNERSHIP
The R3 Partnership Program offers providers an all-in-one regenerative practice program including marketing, consultations and booked procedures!
The information provided by R3 Stem Cell is not a substitute for professional medical advice, diagnosis, or treatment. Individual results may vary and only your medical professional can explain all the risks and potential benefits of any therapy based on your circumstances. R3 Stem Cell does not recommend or endorse any specific tests, products, procedures, opinions, or other information that may be mentioned on this website. Reliance on any information provided by R3 Stem Cell, its employees, others appearing on this website at the invitation of R3 Stem Cell, or other visitors to the website is solely at your own risk. R3 Stem Cell is not responsible for the outcome of your procedure. The FDA considers stem cell therapy experimental at this point.
CALIFORNIA
FLORIDA
GEORGIA
HAWAII
IDAHO
ILLINOIS
INDIANA
IOWA
KANSAS
KENTUCKY
LOUISIANA
MARYLAND
MASSACHUSETTS
MICHIGAN
MINNESOTA
MISSISSIPPI
MISSOURI
NEBRASKA
NEW JERSEY
NEW YORK
NEW MEXICO
NEVADA
NORTH CAROLINA
OHIO
OKLAHOMA
OREGON
PENNSYLVANIA
RHODE ISLAND
SOUTH CAROLINA
SOUTH DAKOTA
TENNESSEE
The USA stem cell leader offers procedures in
7 Countries including:
Copyright © 2017-2024 R3 Stem Cell. All Rights Reserved.
